Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02199028 · ClinicalTrials.gov registry record · Phase 1

Hyaluronidase Effect on Infusion Set Life

A Phase 1 study of Type 1 Diabetes Mellitus, sponsored by Stanford University.

Completed
Registry status
Phase 1
Development phase
30
Enrollment target
1
Study location

NCT02199028: Completed Phase 1 study of Type 1 Diabetes Mellitus, sponsored by Stanford University.

NCT02199028 is a Phase 1 study of Type 1 Diabetes Mellitus that has completed, run by Stanford University. The registered enrollment target is 30 participants, below the 172-participant average among 112 other Type 1 Diabetes Mellitus trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02199028, a Phase 1 study of Type 1 Diabetes Mellitus, has completed, sponsored by Stanford University.

COMPLETED
Registry status
Phase 1
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

This research study examines the effect of hyaluronidase on the length of time of insulin infusion set wear. The aim of the study is to improve the length of time that an infusion set can be worn by infusing hyaluronidase directly into the insulin infusion site.

Primary Outcome

Average (mean) days of wear are presented for each group. A longer period of wear was considered a better outcome.

Conditions Studied

Interventions

  • OTHER Control
  • DRUG Hyaluronidase

Study Locations (1)

California

  • Stanford University - Stanford

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2014-07
Est. Completion 2015-03
Phase Phase 1
Stanford University

1,744 total trials

What the finished NCT02199028 record still lists

NCT02199028 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 172-participant average among 112 other Type 1 Diabetes Mellitus trials with a reported enrollment target (83% lower).

The record links to 1 condition, with Type 1 Diabetes Mellitus appearing as the primary indexed condition, and to 2 interventions - of which Control is the first listed.

NCT02199028 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT02199028 about?

NCT02199028 is a clinical study titled "Hyaluronidase Effect on Infusion Set Life". This research study examines the effect of hyaluronidase on the length of time of insulin infusion set wear. The aim of the study is to improve the length of time that an infusion set can be worn by infusing hyaluronidase directly into the insulin infusion site.

What is the current status of trial NCT02199028?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2014-07. Estimated completion is 2015-03.

What conditions does trial NCT02199028 study?

This clinical trial studies the following conditions: Type 1 Diabetes Mellitus.

What interventions are being tested in trial NCT02199028?

The interventions under investigation include: Control (OTHER), Hyaluronidase (DRUG).

Who is sponsoring clinical trial NCT02199028?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02199028 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Type 1 Diabetes Mellitus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02199028's enrollment target sits among peer trials

30 73rd of 112 higher than 35 of 112 other Type 1 Diabetes Mellitus trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Type 1 Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02199028, the US trial registry maintained by the National Library of Medicine. NCT02199028 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.